Class summary at a glance.

Every drug in the Thyroid Hormone Synthesis Inhibitor class tracked across NADAC, Part D Formulary, Part D Spending, FDA Orange Book, and shortage data. Ranked below by CY24 Part D spend. Click any molecule for the full drug profile.

Molecules in class: 2tracked in Part D
CY24 Part D spend: $19.1Mcombined across class
Total Rx claims: 1.5M438K unique beneficiaries
Generic mfrs (active): 11across all molecules

Every drug in this class, ranked by Part D spend.

CY2024 dataCMS Part D Spending Dashboard

Methimazole

1.4M Part D claims (CY24) · 422K beneficiaries · First FDA approval: 2001-03-27

8 generic mfrs 0 plans require PA

Low NADAC$0.072

→

Avg plan cost$0.094

Part D spend $16.0M 1× spread, current vs floor

Class share

84%

of class CY24 spend

View profile →

Propylthiouracil

58K Part D claims (CY24) · 16K beneficiaries · First FDA approval: 1947-07-28

3 generic mfrs 0 plans require PA

Low NADAC$0.277

→

Avg plan cost$0.277

Part D spend $3.1M 1× spread, current vs floor

Class share

16%

of class CY24 spend

View profile →

Class summary at a glance.

Every drug in this class, ranked by Part D spend.

Related questions.